Italia markets closed

SWTX Jan 2025 65.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,9000-0,0500 (-5,26%)
Alla chiusura: 09:30AM EDT
Schermo intero
Chiusura precedente0,9500
Aperto1,0500
Denaro0,0000
Domanda3,1000
Prezzo d'esercizio65,00
Scadenza2025-01-17
Min-Max giorno0,9000 - 1,0500
Contratto - Min-MaxN/D
Volume2
Open Interest6
  • GlobeNewswire

    SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

    – Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (